Ultra-structural localisation of hepatocellular PKR protein using immuno-gold labelling in chronic hepatitis C virus disease.
The greater resistance of HCV genotype 1 infection to IFN therapy has been partially attributed to functional inhibition of the type 1 interferon induced anti-viral protein PKR in vitro. Whether PKR has antiviral activity against HCV in vivo is unknown. Whilst the ultra-structural localisation of PKR is known in vitro, it is not defined in chronic hepatitis C disease. Using a novel immuno-gold technique we characterised the expression of intrahepatic PKR protein at the ultra-structural level in four patients with chronic HCV disease compared to normal human PBMCs, HepG2 cells and a normal human liver biopsy. All four HCV patients labelled for PKR protein, localising to the nucleus, nucleolus and cytoplasm. Nuclear labelling was confined mainly to the nucleolus and euchromatin. Cytoplasmic labelling was evident within smooth vesicles. Strong immunogold labelling was also evident within the cisternae of the rough endoplasmic reticulum. A similar pattern of ultra-structural nuclear and cytoplasmic PKR protein labelling was seen in PBMCs from healthy donors, HepG2 cells and a normal liver biopsy. The mean nuclear and cytoplasmic count for PKR protein in the HCV group was 21 +/- 4 and 18 +/- 3 gold particles/microm(2), respectively. This represented an increase, though not statistically significant, in nuclear and cytoplasmic labelling for PKR protein in HCV biopsies relative to normal liver tissue.
MacQuillan
Gerry C
GC
Department of Gastroenterology and Hepatology, Sir Charles Gairdner Hospital, Nedlands, WA, Australia. Gerry.MacQuillan@health.wa.gov.au
Caterina
Paul
P
de Boer
Bastiaan
B
Allan
Jane E
JE
Platten
Michael A
MA
Reed
William D
WD
Jeffrey
Gary P
GP
D000328:Adult; D002467:Cell Nucleus / Q000187:drug effects / Q000201:enzymology / Q000648:ultrastructure; D005260:Female; D056945:Hep G2 Cells; D019698:Hepatitis C, Chronic / Q000201:enzymology* / Q000473:pathology / Q000821:virology*; D022781:Hepatocytes / Q000187:drug effects / Q000201:enzymology* / Q000473:pathology / Q000648:ultrastructure*; D006801:Humans; D007150:Immunohistochemistry / Q000379:methods*; D016898:Interferon-alpha / Q000494:pharmacology; D007963:Leukocytes, Mononuclear / Q000187:drug effects / Q000201:enzymology / Q000648:ultrastructure; D008099:Liver / Q000201:enzymology / Q000473:pathology / Q000648:ultrastructure / Q000821:virology; D008297:Male; D008875:Middle Aged; D021381:Protein Transport / Q000187:drug effects; D013194:Staining and Labeling; D019892:eIF-2 Kinase / Q000378:metabolism* / Q000648:ultrastructure*
D016898:Interferon-alpha; D019892:eIF-2 Kinase